A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Agouron Pharmaceuticals

Overview

The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Mycobacterium Avium-Intracellulare Infection HIV Infections

Interventions

Nelfinavir mesylateDRUG

Eligibility

Sex: ALLMin age: 13 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV infection * New diagnosis of MAC bacteremia and \< 7 days of therapy. Prior Medication: Allowed: Patients no more than 7 days of therapy for MAC disease. Exclusion Criteria Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.

Locations (5)

Univ of California / San Diego Treatment Ctr

San Diego, California, United States

Harbor UCLA Med Ctr

Torrance, California, United States

Rush Presbyterian - Saint Luke's Med Ctr

Chicago, Illinois, United States

Boston VA Med Ctr / 151

Boston, Massachusetts, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.